NCT02716792 - A Study to Evaluate Renal Safety of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Disease Due to Breast Cancer | Biotech Hunter

Enrollment

334

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

June 30, 2008

Study Completion Date

August 31, 2008

Conditions

Pain; Bone Neoplasms; Neoplasm Metastasis

Interventions

DRUG

Ibandronate

Participants will receive ibandronate, 6 mg via IV infusion, every 3 weeks for up to 9 cycles. The infusion interval will be either 15 or 60 minutes depending upon treatment group assignment every 3 weeks (9 treatment cycles in total).

Trial Locations (30)

22015

Saint-Brieuc

25030

Besançon

27000

Évreux

29609

Brest

31240

Saint-Jean

35042

Rennes

35768

Saint-Grégoire

37403

Amboise

44202

Nantes

49933

Angers

54511

Vandœuvre-lès-Nancy

59322

Valenciennes

63011

Clermont-Ferrand

64100

Bayonne

67010

Strasbourg

73011

Chambéry

74370

Metz-Tessy

75475

Paris

75674

Paris

75970

Paris

76000

Rouen

78157

Le Chesnay

78190

Trappes

80480

Salouël

83400

Hyères

92100

Boulogne-Billancourt

92200

Neuilly-sur-Seine

92210

Saint-Cloud

94804

Villejuif

05007

Gap

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY